title: Cyclosphosphamide/prednisone for combination immunosuppression and therapy of lymphoproliferative disease.
abstract: Post-transplant lymphoproliferative disease (PTLD) is a well-known complication of solid organ transplantation. While this disorder can often be controlled by decreasing immunosuppression, it is frequently difficult to control the resultant rejection. This case exemplifies this dilemma. To solve this problem, cyclosphosphamide (600 mg/m2) and prednisone (2 mg/kg times 5 days) were given every 3 weeks to simultaneously treat PTLD and provide immunosuppression.
authors.affiliation: Department of Pediatrics, Saint Louis University Health Sciences Center, Missouri 63104, USA.
authors.forename: I C
authors.initials: IC
authors.lastname: Balfour
authors.forename: D
authors.initials: D
authors.lastname: Wall
authors.forename: A
authors.initials: A
authors.lastname: Luisiri
authors.forename: C
authors.initials: C
authors.lastname: Sotelo
authors.forename: T G
authors.initials: TG
authors.lastname: Gross
mesh_terms: D003520:Cyclophosphamide / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use*; D016027:Heart Transplantation / Q000009:adverse effects; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007231:Infant, Newborn; D008232:Lymphoproliferative Disorders / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D011241:Prednisone / Q000627:therapeutic use*
chemical_list: D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D011241:Prednisone